Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Marie Cecile Legdeur"'
Autor:
Jacobien R. Hilberink, Isabelle A. van Zeventer, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Gerwin Huls
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and
Externí odkaz:
https://doaj.org/article/71614de5d82b474e855269ada1ea2dee
Autor:
Jeroen Janssen, Bob Löwenberg, Markus Manz, Mario Bargetzi, Bart Biemond, Peter von dem Borne, Dimitri Breems, Rolf Brouwer, Yves Chalandon, Dries Deeren, Anna Efthymiou, Bjørn-Tore Gjertsen, Carlos Graux, Michael Gregor, Dominik Heim, Urs Hess, Mels Hoogendoorn, Aurelie Jaspers, Asiong Jie, Mojca Jongen-Lavrencic, Saskia Klein, Marjolein van der Klift, Jürgen Kuball, Danielle van Lammeren-Venema, Marie-Cecile Legdeur, Arjan van de Loosdrecht, Johan Maertens, Marinus van Marwijk Kooy, Ine Moors, Marten Nijziel, Florence van Obbergh, Margriet Oosterveld, Thomas Pabst, Marjolein van der Poel, Harm Sinnige, Olivier Spertini, Wim Terpstra, Lidwine Tick, Walter van der Velden, Marie-Christiane Vekemans, Edo Vellenga, Okke de Weerdt, Peter Westerweel, Georg Stüssi, Yvette van Norden, Gert Ossenkoppele
Publikováno v:
Cancers, Vol 13, Iss 4, p 672 (2021)
Treatment results of AML in elderly patients are unsatisfactory. We hypothesized that addition of tosedostat, an aminopeptidase inhibitor, to intensive chemotherapy may improve outcome in this population. After establishing a safe dose in a run-in ph
Externí odkaz:
https://doaj.org/article/24fe32a58d25457ab838d412b4becc0b
Autor:
Markus G. Manz, Harm Sinnige, Marie-Christiane Vekemans, Jürgen Kuball, Yves Chalandon, Dominik Heim, Lidwine W. Tick, Thomas Pabst, Peter E. Westerweel, Marjolein van der Poel, Dimitri Breems, Jeroen Janssen, Marie-Cecile Legdeur, Ine Moors, Carlos Graux, Rolf E. Brouwer, Wim Terpstra, Danielle van Lammeren-Venema, Dries Deeren, Johan Maertens, Okke de Weerdt, Peter A. von dem Borne, Marinus van Marwijk Kooy, Marten R. Nijziel, Arjan A. van de Loosdrecht, Mojca Jongen-Lavrencic, Mels Hoogendoorn, Florence Van Obbergh, Yvette van Norden, Anna Efthymiou, Bjørn-Tore Gjertsen, Georg Stussi, Gert J. Ossenkoppele, Margriet Oosterveld, Bart J. Biemond, Asiong Jie, Mario Bargetzi, Edo Vellenga, Marjolein van der Klift, Aurélie Jaspers, Saskia K. Klein, Olivier Spertini, Walter J.F.M. van der Velden, Urs Hess, Bob Löwenberg, Michael Gregor
Publikováno v:
Cancers, vol. 13, no. 4, pp. 672
Cancers, Vol. 13, No 4 (2021) P. 672
Cancers
Volume 13
Issue 4
Cancers, 13
Janssen, J, Löwenberg, B, Manz, M, Bargetzi, M, Biemond, B, von dem Borne, P, Breems, D, Brouwer, R, Chalandon, Y, Deeren, D, Efthymiou, A, Gjertsen, B T, Graux, C, Gregor, M, Heim, D, Hess, U, Hoogendoorn, M, Jaspers, A, Jie, A, Jongen-Lavrencic, M, Klein, S, van der Klift, M, Kuball, J, van Lammeren-Venema, D, Legdeur, M C, van de Loosdrecht, A, Maertens, J, Kooy, M V M, Moors, I, Nijziel, M, van Obbergh, F, Oosterveld, M, Pabst, T, van der Poel, M, Sinnige, H, Spertini, O, Terpstra, W, Tick, L, van der Velden, W, Vekemans, M C, Vellenga, E, de Weerdt, O, Westerweel, P, Stüssi, G, van Norden, Y & Ossenkoppele, G 2021, ' Inferior outcome of addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with aml and high risk mds ', Cancers, vol. 13, no. 4, 672, pp. 1-11 . https://doi.org/10.3390/cancers13040672
Cancers, Vol. 13, no. 4, p. 672 [1-11] (2021)
Cancers, Vol 13, Iss 672, p 672 (2021)
Cancers, 13(4):672, 1-11. Multidisciplinary Digital Publishing Institute (MDPI)
Janssen, Jeroen; Löwenberg, Bob; Manz, Markus; Bargetzi, Mario; Biemond, Bart; Borne, Peter von dem; Breems, Dimitri; Brouwer, Rolf; Chalandon, Yves; Deeren, Dries; Efthymiou, Anna; Gjertsen, Bjørn-Tore; Graux, Carlos; Gregor, Michael; Heim, Dominik; Hess, Urs; Hoogendoorn, Mels; Jaspers, Aurelie; Jie, Asiong; Jongen-Lavrencic, Mojca; ... (2021). Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers, 13(4) MDPI AG 10.3390/cancers13040672
Cancers, 13, 4
Cancers, 13(4):672. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 13(4):672. MDPI AG
CANCERS
Cancers, Vol. 13, No 4 (2021) P. 672
Cancers
Volume 13
Issue 4
Cancers, 13
Janssen, J, Löwenberg, B, Manz, M, Bargetzi, M, Biemond, B, von dem Borne, P, Breems, D, Brouwer, R, Chalandon, Y, Deeren, D, Efthymiou, A, Gjertsen, B T, Graux, C, Gregor, M, Heim, D, Hess, U, Hoogendoorn, M, Jaspers, A, Jie, A, Jongen-Lavrencic, M, Klein, S, van der Klift, M, Kuball, J, van Lammeren-Venema, D, Legdeur, M C, van de Loosdrecht, A, Maertens, J, Kooy, M V M, Moors, I, Nijziel, M, van Obbergh, F, Oosterveld, M, Pabst, T, van der Poel, M, Sinnige, H, Spertini, O, Terpstra, W, Tick, L, van der Velden, W, Vekemans, M C, Vellenga, E, de Weerdt, O, Westerweel, P, Stüssi, G, van Norden, Y & Ossenkoppele, G 2021, ' Inferior outcome of addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with aml and high risk mds ', Cancers, vol. 13, no. 4, 672, pp. 1-11 . https://doi.org/10.3390/cancers13040672
Cancers, Vol. 13, no. 4, p. 672 [1-11] (2021)
Cancers, Vol 13, Iss 672, p 672 (2021)
Cancers, 13(4):672, 1-11. Multidisciplinary Digital Publishing Institute (MDPI)
Janssen, Jeroen; Löwenberg, Bob; Manz, Markus; Bargetzi, Mario; Biemond, Bart; Borne, Peter von dem; Breems, Dimitri; Brouwer, Rolf; Chalandon, Yves; Deeren, Dries; Efthymiou, Anna; Gjertsen, Bjørn-Tore; Graux, Carlos; Gregor, Michael; Heim, Dominik; Hess, Urs; Hoogendoorn, Mels; Jaspers, Aurelie; Jie, Asiong; Jongen-Lavrencic, Mojca; ... (2021). Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers, 13(4) MDPI AG 10.3390/cancers13040672
Cancers, 13, 4
Cancers, 13(4):672. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 13(4):672. MDPI AG
CANCERS
Simple Summary Treatment results of acute myeloid leukemia (AML) in elderly patients are unsatisfactory. We investigated in an open label randomized phase II study whether addition of tosedostat, an aminopeptidase inhibitor, to intensive chemotherapy
Autor:
Marie-Christiane Vekemans, Wim H. van der Putten, Johan Maertens, Florentien E. M. in ’t Hout, Raynier Devillier, Bart J. Biemond, Jurjen Versluis, Thomas Pabst, Gert J. Ossenkoppele, Jan J. Cornelissen, Peter J. M. Valk, Roel Willemze, Bob Löwenberg, Markus G. Manz, Frédéric Baron, Giovanna Meloni, Bert A. van der Reijden, Harry C. Schouten, Gerwin Huls, Marie-Cecile Legdeur, Edo Vellenga, Jakob Passweg, Jürgen Kuball
Publikováno v:
Leukemia, 31(1), 26-33. Nature Publishing Group
Leukemia, 31, 26-33. Nature Publishing Group
Leukemia, Vol. 31, no.1, p. 26-33 (2016)
Leukemia, 31, 1, pp. 26-33
Leukemia, 31, 26. Nature Publishing Group
Leukemia, 31, 26-33
Versluis, J, In'T Hout, F E M, Devillier, R, Van Putten, W L J, Manz, M G, Vekemans, M C, Legdeur, M C, Passweg, J R, Maertens, J, Kuball, J, Biemond, B J, Valk, P J M, Van Der Reijden, B A, Meloni, G, Schouten, H C, Vellenga, E, Pabst, T, Willemze, R, Löwenberg, B, Ossenkoppele, G, Baron, F, Huls, G & Cornelissen, J J 2017, ' Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio ', Leukemia, vol. 31, no. 1, pp. 26-33 . https://doi.org/10.1038/leu.2016.183
Leukemia, 31, 26-33. Nature Publishing Group
Leukemia, Vol. 31, no.1, p. 26-33 (2016)
Leukemia, 31, 1, pp. 26-33
Leukemia, 31, 26. Nature Publishing Group
Leukemia, 31, 26-33
Versluis, J, In'T Hout, F E M, Devillier, R, Van Putten, W L J, Manz, M G, Vekemans, M C, Legdeur, M C, Passweg, J R, Maertens, J, Kuball, J, Biemond, B J, Valk, P J M, Van Der Reijden, B A, Meloni, G, Schouten, H C, Vellenga, E, Pabst, T, Willemze, R, Löwenberg, B, Ossenkoppele, G, Baron, F, Huls, G & Cornelissen, J J 2017, ' Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio ', Leukemia, vol. 31, no. 1, pp. 26-33 . https://doi.org/10.1038/leu.2016.183
Contains fulltext : 169931.pdf (Publisher’s version ) (Closed access) Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients wit
Autor:
Carlos Graux, Mojca Jongen-Lavrencic, Thomas Pabst, Harry C. Schouten, Jurjen Versluis, Jakob Passweg, Jeroen Janssen, Vincent H.J. van der Velden, Marie-Christiane Vekemans, Mels Hoogendoorn, Wendelien Zeijlemaker, Burak Kalin, Okke de Weerdt, Marie-Cecile Legdeur, Pierre W. Wijermans, Marinus van Marwijk Kooy, Bart J. Biemond, Markus G. Manz, Gert J. Ossenkoppele, Gerrit Jan Schuurhuis, J. Kuball, Mario Bargetzi, Bob Löwenberg, Jan J. Cornelissen
Publikováno v:
JCO Precision Oncology, 2017(1), 1-13. American Society of Clinical Oncology
JCO precision oncology, Vol. 1, no.1, p. 1-13 (2017)
JCO precision oncology, Vol. 1, no.1, p. 1-13 (2017)
Purpose The detection of minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) may improve future risk-adapted treatment strategies. We assessed whether MRD-positive and MRD-negative patients with AML benefit differently from t
Autor:
K.S. van der Lee, H. Wilmink, Remy Klaassen, Marie-Cecile Legdeur, Dick J. Richel, H.W.M. van Laarhoven, Aart J. Nederveen, Esther N. Pijnappel, M. Pleunis van Empel
Publikováno v:
Annals of Oncology. 30:v265
Background In pancreatic cancer desmoplasia is a central feature of the tumour microenvironment. Growing evidence suggests that by targeting both tumour cells and tumour stoma, treatment efficacy is increased. LDE225 is a pharmacological Hedgehog sig
Autor:
Thomas, Pabst, Edo, Vellenga, Wim, van Putten, Harry C, Schouten, Carlos, Graux, Marie-Christiane, Vekemans, Bart, Biemond, Peter, Sonneveld, Jakob, Passweg, Leo, Verdonck, Marie-Cecile, Legdeur, Matthias, Theobald, Emanuel, Jacky, Mario, Bargetzi, Johan, Maertens, Gert Jan, Ossenkoppele, Bob, Löwenberg, M, Van Marwijk Kooy
Publikováno v:
Blood, 119(23), 5367-5373. American Society of Hematology
Blood, 119(23), 5367-5373. AMER SOC HEMATOLOGY
Pabst, T, Vellenga, E, van Putten, W, Schouten, H C, Graux, C, Vekemans, M C, Biemond, B, Sonneveld, P, Passweg, J, Verdonck, L, Legdeur, M C, Theobald, M, Jacky, E, Bargetzi, M, Maertens, J, Ossenkoppele, G J & Lowenberg, B 2012, ' Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine ', Blood, vol. 119, no. 23, pp. 5367-5373 . https://doi.org/10.1182/blood-2011-11-389841
Blood, 119(23), 5367-5373. The American Society of Hematology
Blood, 119(23), 5367-5373. AMER SOC HEMATOLOGY
Pabst, T, Vellenga, E, van Putten, W, Schouten, H C, Graux, C, Vekemans, M C, Biemond, B, Sonneveld, P, Passweg, J, Verdonck, L, Legdeur, M C, Theobald, M, Jacky, E, Bargetzi, M, Maertens, J, Ossenkoppele, G J & Lowenberg, B 2012, ' Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine ', Blood, vol. 119, no. 23, pp. 5367-5373 . https://doi.org/10.1182/blood-2011-11-389841
Blood, 119(23), 5367-5373. The American Society of Hematology
The clinical value of chemotherapy sensitization of acute myeloid leukemia (AML) with G-CSF priming has remained controversial. Cytarabine is a key constituent of remission induction chemotherapy. The effect of G-CSF priming has not been investigated
Autor:
Maarten J. Deenen, Henk Boot, Annemieke Cats, Marie-Cecile Legdeur, Didier Meulendijks, Jan H.M. Schellens, Jos H. Beijnen
Publikováno v:
Cancer Chemotherapy and Pharmacology, 76(6), 1285. Springer Verlag
Purpose: The prognosis of gastroesophageal cancer is poor, and current regimens are associated with limited efficacy. The purpose of this study was to explore the safety and preliminary efficacy of docetaxel, oxaliplatin plus capecitabine for advance
Autor:
Geke A. P. Hospers, Bruno van der Holt, Rudi M. H. Roumen, Henk M.W. Verheul, Rob L. H. Jansen, Pieter J. Tanis, Sandra A Radema, Ninos Ayez, Nelly van der Meer, Ferry A.L.M. Eskens, Hans de Wilt, Dirk J. Grünhagen, Cornelis J. A. Punt, Marie-Cecile Legdeur, Richard van Hillegersberg, Eric P. van der Stok, Joost M. Klaase, Cornelis H. C. Dejong, Gerard Vreugdenhil, Esther van Meerten, Koert P. de Jong, Cornelis Verhoef
Publikováno v:
BMC Cancer, 15:180. BioMed Central
BMC Cancer, 15
BMC Cancer
BMC Cancer, 15:180. BioMed Central Ltd
BMC Cancer, 15. BioMed Central Ltd.
BMC cancer, 15(1). BioMed Central
BMC Cancer, 15:180. BMC
Ayez, N, van der Stok, E P, de Wilt, H, Radema, S A, van Hillegersberg, R, Roumen, R M, Vreugdenhil, G, Tanis, P J, Punt, C J, Dejong, C H, Jansen, R L, Verheul, H M, de Jong, K P, Hospers, G A, Klaase, J M, Legdeur, M C, van Meerten, E, Eskens, F A, van der Meer, N, van der Holt, B, Verhoef, C & Grunhagen, D J 2015, ' Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial ', BMC Cancer, vol. 15, 180 . https://doi.org/10.1186/s12885-015-1199-8
BMC Cancer, 15
BMC Cancer
BMC Cancer, 15:180. BioMed Central Ltd
BMC Cancer, 15. BioMed Central Ltd.
BMC cancer, 15(1). BioMed Central
BMC Cancer, 15:180. BMC
Ayez, N, van der Stok, E P, de Wilt, H, Radema, S A, van Hillegersberg, R, Roumen, R M, Vreugdenhil, G, Tanis, P J, Punt, C J, Dejong, C H, Jansen, R L, Verheul, H M, de Jong, K P, Hospers, G A, Klaase, J M, Legdeur, M C, van Meerten, E, Eskens, F A, van der Meer, N, van der Holt, B, Verhoef, C & Grunhagen, D J 2015, ' Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial ', BMC Cancer, vol. 15, 180 . https://doi.org/10.1186/s12885-015-1199-8
Contains fulltext : 153481.pdf (Publisher’s version ) (Open Access) BACKGROUND: Efforts to improve the outcome of liver surgery by combining curative resection with chemotherapy have failed to demonstrate definite overall survival benefit. This may
Autor:
G. Paardekooper, Dankert Woutersen, A. Slot, J.Th.M. Plukker, W. E. Fiets, Christina T. Muijs, Geke A. P. Hospers, Marie-Cecile Legdeur, Jannet C. Beukema, Justin K. Smit, Johannes G. M. Burgerhof, J.W.B. de Groot, Karin Muller, Judith Honing
Publikováno v:
Annals of Oncology, 25(3), 638-643. Oxford University Press
We compared retrospectively carboplatin/paclitaxel to cisplatinum/5-FU as dCRT treatment in esophageal cancer patients. We found comparable outcome, but lower toxicity rates and higher treatment compliance in the carboplatin/paclitaxel group. Therefo